<SEC-DOCUMENT>0001493152-26-007701.txt : 20260223
<SEC-HEADER>0001493152-26-007701.hdr.sgml : 20260223
<ACCEPTANCE-DATETIME>20260223110027
ACCESSION NUMBER:		0001493152-26-007701
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260223
FILED AS OF DATE:		20260223
DATE AS OF CHANGE:		20260223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		26662723

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>February
2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B> 001-41386</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9<SUP>th
</SUP>Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 23, 2026, OKYO Pharma LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing that its abstract has been accepted for
presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, taking place May 3-7, 2026, in Denver,
Colorado. Chief Scientific Officer Raj Patil, Ph.D., will share the data in a presentation titled: &ldquo;First-in-Human Study of Urcosimod
to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company&rsquo;s Registration
Statement on Form F-3 (Reg. No. 333-293145)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    February 23, 2026</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Keeren Shah</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
    Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">News Announcement, dated February 23, 2026</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OKYO
Abstract Selected for Presentation at Premier Global Ophthalmology Congress</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London
and New York, NY, February 23, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational
therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that its abstract has
been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, taking place May
3-7, 2026, in Denver, Colorado.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Scientific Officer Raj Patil, Ph.D., will share the data in a presentation titled: &ldquo;First-in-Human Study of Urcosimod to Treat
Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
presentation highlights positive results from OKYO&rsquo;s recently completed proof-of-concept Phase 2a clinical trial of urcosimod,
a novel, non-opioid, preservative-free eye-drop therapy with dual pain-relieving and anti-inflammatory activity for neuropathic corneal
pain (NCP). The first-in-human study in NCP patients demonstrated clinically meaningful reductions in pain&mdash;as measured by the Visual
Analogue Scale (VAS)&mdash;along with improvements in quality-of-life metrics. In addition, urcosimod demonstrated the potential to help
restore corneal nerve structure in patients suffering from neuropathic corneal pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuropathic
corneal pain is a debilitating chronic ocular condition characterized by severe nerve-related pain without visible surface damage and
currently has no FDA-approved treatments. Urcosimod holds FDA Fast Track designation for NCP and is the first candidate to receive IND
clearance specifically for this indication. Following encouraging Phase 2a proof-of-concept results, OKYO is advancing urcosimod into
a planned larger multicenter Phase 2b/3 trial (approximately 150 patients) to further evaluate its efficacy and safety, with initiation
expected in the coming months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are honored that our urcosimod data has been selected for presentation at ARVO 2026, one of the world&rsquo;s leading forums for vision
and ophthalmology research,&rdquo; said Raj Patil, Ph.D., Chief Scientific Officer of OKYO Pharma. &ldquo;These first-in-human results
underscore urcosimod&rsquo;s potential to address a significant unmet need in NCP by providing meaningful pain relief and enhancing patients&rsquo;
quality of life. We look forward to sharing these findings with the scientific community and continuing to advance this promising therapy.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ARVO Annual Meeting attracts thousands of leading researchers, clinicians, and industry professionals focused on advancing eye and vision
science.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously announced, urcosimod was granted the first IND application for the treatment of patients with NCP and was awarded fast track
designation by the Food and Drug Administration (FDA). The company expects to initiate a ~150 subject Phase 2b/3 multiple-dose study
of urcosimod to treat NCP in the first half of this year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Neuropathic Corneal Pain (NCP)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuropathic
corneal pain (NCP) is a chronic, often debilitating condition characterized by severe pain and sensitivity of the eyes, and in some cases
the face or head. It is thought to result from damage or dysfunction of corneal sensory nerves, often in combination with inflammatory
processes, and may occur in patients with a range of underlying ophthalmic conditions. There are currently no FDA-approved therapies
specifically for NCP, resulting in patients being treated with limited or no success using various topical and systemic medications in
an off-label manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Urcosimod (formerly called OK-101)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Urcosimod
is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of
the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been
shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain
mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked
Phase 2a trial involving 18 neuropathic corneal pain subjects. Urcosimod has shown significant pain reduction in an earlier 240 subject
Phase 2, multi-center, double-masked, placebo-controlled trial in DED, which supports the development rationale in NCP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OKYO Pharma </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic
corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused
on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed
a successful phase 2 trial of its flagship drug urcosimod in subjects with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose
study of urcosimod to treat NCP in the first half of this year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further information, please visit <U>www.okyopharma.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather
are based on the Company&rsquo;s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words
such as &lsquo;anticipates,&rsquo; &lsquo;expects,&rsquo; &lsquo;intends,&rsquo; &lsquo;plans,&rsquo; &lsquo;believes,&rsquo; &lsquo;seeks,&rsquo;
&lsquo;estimates,&rsquo; and similar expressions are intended to identify forward-looking statements. These statements are not guarantees
of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company&rsquo;s
control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking
statements. These and additional risks and uncertainties are described more fully in the company&rsquo;s filings with the SEC, including
those factors identified as &ldquo;Risk Factors&rdquo; in our most recent Annual Report on Form 20-F, for the fiscal year ended March
31, 2025. The company cautions security holders and prospective security holders not to place undue reliance on these forward-looking
statements, which reflect the view of the company only as of the date of this announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the statements are made. The company will not undertake any obligation to
release publicly any revisions or updates to these forward-looking statements, except as may be required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
further inquiries:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma Ltd</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Spencer, Business Development, and Investor Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44
(0) 207 495 2379</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<U>info@okyopharma.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  R -D# 2(  A$! Q$!_\0
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M#.)&N9%;YC<D'*C/\'WFZG //ZGV5E;Z=:0VMI!':VL*".*&% B(H& J@<
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M\:E@"A;=D'E6<=0*Z:JP]>FZ=*2O'X=TWWNVNNYC3=:E-3J)V>_Z6]-CKO\
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A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
